Top of this page
Skip navigation, go straight to the content
Categories
-
UCB Announces New Data from its Epilepsy Portfolio Presented on the American Academy of Neurology Virtual Platform
Jun 24, 2020
Six poster presentations highlight clinical data on NAYZILAM® (midazolam) nasal spray CIV and BRIVIACT® (brivaracetam) CV in addition to epilepsy-related health economics outcomes research
Atlanta, Ga., June 24, 2020: UCB today announced six posters selected for presentation at the 72nd American Academy of Neurology (AAN) annual meeting, available online via the 2020 AAN Science Highlights virtual platform, which replaced the in-person event previously cancelled due to the COVID-19 pandemic. The abstracts were also published in the online supplement to Neurology.
-
Press Release: First Presentations of Bimekizumab Phase 3 Data Demonstrate Superior Skin Clearance Over Placebo and Stelara at Week 16 in Adults with Moderate-to-Severe Plaque Psoriasis
Jun 12, 2020
• Data from the Phase 3 BE VIVID and BE READY studies show that bimekizumab-treated patients with psoriasis achieved significant skin clearance at week 16, rapid response after one dose, and durability of response up to a year
• Results support the importance of selectively inhibiting IL-17F, in addition to IL-17A, with bimekizumab -
Press Release: UCB acquires Engage Therapeutics: Staccato Alprazolam - A potential solution for acute on-demand seizure management for people living with epilepsy
Jun 05, 2020
• Underlines UCB’s leadership in epilepsy by adding Staccato® Alprazolam, a drug-device-combination with the potential to be the first on-demand, single-use treatment to rapidly terminate an active epileptic seizure -
UCB completes the acquisition of Ra Pharmaceuticals – to deliver differentiated therapies to patients
Apr 02, 2020
UCB completes the acquisition of Ra Pharmaceuticals – to deliver differentiated therapies to patients. -
Press Release: UCB Presents Final Results from Phase II Study of Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) at 2019 ASH Annual Meeting
Dec 09, 2019
UCB Presents Final Results from Phase II Study of Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) at 2019 ASH Annual Meeting -
Press Release: Bimekizumab Phase 3 Psoriasis Study Demonstrates Superiority Versus Humira®
Dec 06, 2019
Bimekizumab Phase 3 Psoriasis Study Demonstrates Superiority Versus Humira® -
Press Release: UCB Presents New Data Demonstrating Commitment to Epilepsy at 2019 American Epilepsy Society Meeting
Dec 05, 2019
• 14 scientific presentations will cover UCB’s pipeline assets, epilepsy-specific research, and licensed medicines, including NAYZILAM, now available for the acute treatment of seizure clusters in epilepsy patients 12 years of age and older
• Friday evening symposium on “Epilepsy Treatment Update for Patients Suffering from Seizure Clusters” includes Epilepsy Foundation’s project on seizure emergencies and a panel discussion on the misconceptions around seizure clusters -
Press Release: UCB Announces availability of NAYZILAM® (midazolam) Nasal Spray CIV, the first and only nasal rescue treatment for seizure clusters in the U.S.
Nov 25, 2019
• NAYZILAM will be available in retail pharmacies on December 2, 2019
• Copay support and a patient assistance program will be provided by UCB for eligible NAYZILAM patients* -
Press Release: Bimekizumab Positive Results Confirmed in Second Phase 3 Psoriasis Study
Nov 15, 2019
• The Phase 3 BE READY study, evaluating the efficacy and safety of bimekizumab versus placebo in adults with moderate-to-severe chronic plaque psoriasis, met all primary and ranked secondary endpoints1
• UCB plans to submit applications to regulatory authorities for approval of bimekizumab to treat adults with moderate-to-severe plaque psoriasis in mid-2020 -
Press Release: UCB Presents New Data From Rheumatology Portfolio Addressing Unmet Needs in Axial Spondyloarthritis, Psoriatic Arthritis and Lupus at 2019 ACR/ARP
Nov 08, 2019
UCB Presents New Data From Rheumatology Portfolio Addressing Unmet Needs in Axial Spondyloarthritis, Psoriatic Arthritis and Lupus at 2019 ACR/ARP
UCB U.S. News
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- September 2017